New drug before surgery for resectable bile duct cancer
Part of Cancer clinical trials.
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- You have liver (intrahepatic) cholangiocarcinoma confirmed by pathology, and you haven’t had any cancer drug treatment yet
- Your cancer is planned for surgery and has high-risk features (like larger size, multiple tumors, nearby blood vessel invasion, or lymph node suspicion)
- You must be well enough for treatment and surgery (performance status 0) and your liver, kidney, and blood counts are within required ranges
- You must have no spread of cancer to distant organs, and your hepatitis B/C infection levels (if present) must be controlled
- You agree to birth control during the study and to provide stored tumor tissue (or new scans/biopsies)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests a new combination of three drugs (adebrelimab, surufatinib, and liposomal irinotecan) given directly into the liver artery for advanced intrahepatic cholangiocarcinoma. The goal is to see if this approach can shrink or control the cancer.
This trial tests whether combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) can help people with intrahepatic bile duct cancer that hasn't been treated before. It aims to see if this triple approach is safe and effective.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.